Pharmaceutical

ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success

Shares in the pharma company rose 40% in premarket trading.

May 25, 2024 - 04:00
ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
Shares in the pharma company rose 40% in premarket trading.
Read the original article

Tags:

Previous Article

ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody

Next Article

FDA advisory committee reviews Novo Nordisk insulin icodec for T1D

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

XB-002 by Exelixis for Breast Cancer: Likelihood of App...

Dec 22, 2023

STAT+: 2024 could be a turning point for the regulation of AI in health care

STAT+: 2024 could be a turning point for the regulation...

Jan 2, 2024

STAT+: Insulin makers, PBMs echo old finger-pointing in Senate hearing

STAT+: Insulin makers, PBMs echo old finger-pointing in...

May 11, 2023